# Standard Biotools Inc.: Form 10-Q for the period ended Jun 30, 2013

- Company: [Standard Biotools Inc.](/companies/lab.md) (CIK 1162194)
- Form: 10-Q
- Filed: 2013-08-07
- Accepted by EDGAR: Aug 7, 2013, 17:30 ET
- Period: 2013-06-30
- Accession: 0001193125-13-324552
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1162194/000119312513324552/d556920d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1162194/000119312513324552/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-04-01 to 2013-06-30 | $17.5m | us-gaap:Revenues |
| Revenue | 6 months, 2013-01-01 to 2013-06-30 | $32.0m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-04-01 to 2013-06-30 | $4.9m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2013-01-01 to 2013-06-30 | $9.1m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2013-04-01 to 2013-06-30 | $5.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2013-01-01 to 2013-06-30 | $9.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2013-04-01 to 2013-06-30 | $11.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2013-01-01 to 2013-06-30 | $22.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2013-04-01 to 2013-06-30 | −$4.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2013-01-01 to 2013-06-30 | −$9.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-04-01 to 2013-06-30 | $2.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2013-01-01 to 2013-06-30 | $12.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-04-01 to 2013-06-30 | $15.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2013-01-01 to 2013-06-30 | $53.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-04-01 to 2013-06-30 | −$4.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2013-01-01 to 2013-06-30 | −$7.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-04-01 to 2013-06-30 | −$0.16 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2013-01-01 to 2013-06-30 | −$0.30 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2013-01-01 to 2013-06-30 | −$3.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2013-01-01 to 2013-06-30 | $912.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-06-30 | $32.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-06-30 | $80.5m | us-gaap:AssetsCurrent |
| Total assets | at 2013-06-30 | $112.0m | us-gaap:Assets |
| Current liabilities | at 2013-06-30 | $11.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-06-30 | $13.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-06-30 | $98.4m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1162194/000119312513324552/d556920d10q.htm

Filed Aug 7, 2013.
Source: SEC EDGAR, the filing index for accession 0001193125-13-324552. Last ingested by Listed: Nov 5, 2026, 21:16 ET. No prices; not investment advice.
